To measure the impact of HMGB1-RAGE signaling on vascular permeability, HUVEC monolayers grown on 8 μm Transwell chambers were stimulated with CMs from uninfected or oHSV-infected glioma cells in the presence or absence of a RAGE-blocking antibody (2 μg/mL) or purified esRAGE (200 ng/mL), and the amount of Evan’s Blue albumin (EBA) that permeated the monolayer to the lower chamber was measured to evaluate vascular leakiness (Figure 2B). This evidence concerns the gene HMGB1 and glioma.